预存抗因子VIII免疫通过细胞毒性CD8 T细胞改变白消安预处理后靶向血小板的因子VIII植入
本研究在血友病A伴抑制物小鼠模型中探索血小板靶向因子VIII基因治疗丢失的机制。结果显示预存免疫通过细胞毒性CD8 T细胞攻击2bF8Tg-Sca-1+细胞导致血小板因子VIII表达丢失,而清除CD8 T细胞可恢复表达。
要点
- 预存抗因子VIII免疫使血小板因子VIII表达在HSCT后丢失,但在骨髓移植后持续表达。
- 白消安预处理联合CD8 T细胞清除可恢复预存免疫小鼠的血小板因子VIII表达。
- 2bF8Tg-Sca-1+细胞是因子VIII致敏CD8 T细胞的靶细胞,而非血小板/巨核细胞。
核心结论
- 预存免疫可通过细胞毒性CD8 T细胞介导的途径改变2bF8Tg-Sca-1+细胞的植入。
- 充分清除因子VIII致敏的CD8 T细胞对伴抑制物血友病A血小板基因治疗的成功至关重要。
研究设计与样本
- 在因子VIII基因敲除小鼠中,先用重组人因子VIII免疫诱导抑制物,再用白消安预处理后行2bF8转基因小鼠全骨髓移植或Sca-1+造血干细胞移植。
- 部分实验在白消安基础上加用抗胸腺细胞球蛋白或抗CD8抗体。
- 采用干扰素γ-酶联免疫斑点 assay 评估靶细胞亚群。
- 使用B细胞缺陷纯合突变小鼠判断血小板因子VIII丢失是否由抗体依赖细胞介导的细胞毒性所致。
主要发现
- 2bF8Tg骨髓移植后血小板因子VIII表达持续,而2bF8Tg造血干细胞移植后表达丢失。
- 白消安预处理联合CD8 T细胞清除可恢复2bF8Tg造血干细胞移植受者的血小板因子VIII表达。
- 酶联免疫斑点分析显示因子VIII致敏CD8 T细胞可被2bF8Tg-Sca-1+细胞有效再刺激并分泌干扰素γ,但未被2bF8Tg血小板/巨核细胞刺激。
- 在因子VIII致敏的B细胞缺陷纯合突变小鼠中,白消安预处理后移植2bF8Tg-Sca-1+细胞未检测到因子VIII表达。
临床怎么用
- 原文结论指出充分清除因子VIII致敏的CD8 T细胞对伴抑制物血友病A血小板基因治疗的成功至关重要。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We previously demonstrated that busulfan preconditioning enabled sustained therapeutic platelet-derived factor VIII (FVIII) expression in naïve FVIIInull mice transplanted with 2bF8-transduced Sca-1+ cells. However, in mice with pre-existing inhibitors, platelet-FVIII expression was lost. OBJECTIVE: In this study, we aimed to describe the mechanism of this platelet-FVIII loss. METHODS: We monitored platelet-FVIII expression in FVIIInull mice that were immunized with rhFVIII to induce inhibitors and subsequently conditioned with busulfan before whole bone marrow transplantation or Sca-1+ hematopoietic stem cell transplantation (HSCT) from 2bF8 transgenic (2bF8Tg) mice. Busulfan with or without antithymocyte globulin or anti-CD8 antibody was employed before 2bF8Tg HSCT. Interferon gamma-ELISpot assay was used to assess which subset of cells was the target in platelet-FVIII loss. B-cell-deficient homozygous mutant mice were used to determine whether platelet-FVIII loss in FVIII-primed mice was mediated by antibody-dependent cellular cytotoxicity. RESULTS: Platelet-FVIII expression was sustained in 2bF8Tg bone marrow transplantation but not in 2bF8Tg HSCT recipients. CD8 T-cell depletion in addition to busulfan preconditioning restored platelet-FVIII expression in 2bF8Tg-HSCT recipients. ELISpot analyses showed that FVIII-primed CD8 T cells were efficiently restimulated by 2bF8Tg-Sca-1+ cells and secreted interferon gamma, but were not stimulated by 2bF8Tg platelets/megakaryocytes, suggesting that 2bF8Tg-Sca-1+ cells are targets for FVIII-primed CD8 T cells. When 2bF8Tg-Sca-1+ cells were transplanted into FVIII-primed homozygous mutant mice preconditioned with busulfan, no FVIII expression was detected, suggesting that antibody-dependent cellular cytotoxicity was not the mechanism of platelet-FVIII loss in FVIII-primed mice. CONCLUSION: Pre-existng immunity can alter the engraftment of 2bF8Tg-Sca-1+ cells through the cytotoxic CD8 T-cell-mediated pathway. Sufficient eradication of FVIII-primed CD8 T cells is critical for the success of platelet gene therapy in hemophilia A with inhibitors.
引用
- Jing W, Baumgartner CK, Xue F, et al. Pre-existing anti-factor VIII immunity alters therapeutic platelet-targeted factor VIII engraftment following busulfan conditioning through cytotoxic CD8 T cells. J Thromb Haemost. 2022. PMID: 36696197. doi:10.1016/j.jtha.2022.10.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。